Literature DB >> 12064811

Modulatory effects of plasma and colonic milieu of patients with ulcerative colitis on neutrophil reactive oxygen species production in presence of a novel antioxidant, rebamipide.

A Farhadi1, A Keshavarzian, L R Fitzpatrick, E Mutlu, Y Zhang, A Banan.   

Abstract

Rebamipide protects gastrointestinal mucosal integrity against reactive oxygen species (ROS). The effect of rebamipide on the capability of PMNs to produce ROS in the presence of plasma and rectal dialysates (RD) of control and ulcerative colitis (UC) subjects was evaluated. We recruited six healthy volunteers for obtaining PMNs, control plasma, and control RD and six patients with inactive UC for obtaining plasma and RD. PMNs were activated using fMLP, and ROS was measured by fluorescent microplate assay (DCFD). Rebamipide significantly inhibited the neutrophil respiratory burst by 45%. Plasma from both control subjects and UC patients significantly blunted the fMLP-induced respiratory burst. However, the plasma of the UC patients was significantly less inhibitory than the plasma of control subjects. RD from control subjects significantly blunted the fMLP-induced respiratory burst while, RD from patients with UC did not. Rebamipide maintained its antioxidant effects in the presence of plasma or RD obtained from both controls and UC patients. In conclusion, partial loss of the inhibitory effects of plasma and RD in patients with UC may contribute to oxidative-induced tissue damage in UC and rebamipide antioxidant properties were not hampered by the biological milieu of patients with UC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12064811     DOI: 10.1023/a:1015382800434

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  53 in total

1.  Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease.

Authors:  S J McKenzie; M S Baker; G D Buffinton; W F Doe
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

2.  Rebamipide protects against activation of neutrophils by Helicobacter pylori.

Authors:  N Yoshida; T Yoshikawa; S Iinuma; M Arai; S Takenaka; K Sakamoto; T Miyajima; Y Nakamura; N Yagi; Y Naito; F Mukai; M Kondo
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

3.  Impairment of antioxidants in colonic epithelial cells isolated from trinitrobenzene sulphonic acid-induced colitis rats. Protective effect of rebamipide.

Authors:  W L Zea-Iriarte; K Makiyama; S Goto; K Murase; Y Urata; I Sekine; K Hara; T Kondo
Journal:  Scand J Gastroenterol       Date:  1996-10       Impact factor: 2.423

4.  Oxidant-induced disruption of intestinal epithelial barrier function: role of protein tyrosine phosphorylation.

Authors:  R K Rao; R D Baker; S S Baker; A Gupta; M Holycross
Journal:  Am J Physiol       Date:  1997-10

5.  Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis.

Authors:  S Sedghi; J Z Fields; M Klamut; G Urban; M Durkin; D Winship; D Fretland; M Olyaee; A Keshavarzian
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

6.  OPC-compounds prevent oxidant-induced carbonylation and depolymerization of the F-actin cytoskeleton and intestinal barrier hyperpermeability.

Authors:  A Banan; L Fitzpatrick; Y Zhang; A Keshavarzian
Journal:  Free Radic Biol Med       Date:  2001-02-01       Impact factor: 7.376

7.  Impaired activation of the neutrophil oxidative metabolism in chronic inflammatory bowel disease.

Authors:  H W Verspaget; J Elmgreen; I T Weterman; A S Peña; P Riis; C B Lamers
Journal:  Scand J Gastroenterol       Date:  1986-11       Impact factor: 2.423

8.  Antiulcer mechanism of action of rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers in rats.

Authors:  K Ogino; T Hobara; H Ishiyama; K Yamasaki; H Kobayashi; Y Izumi; S Oka
Journal:  Eur J Pharmacol       Date:  1992-02-25       Impact factor: 4.432

9.  Colitis and colonic mucosal barrier dysfunction.

Authors:  K R Gardiner; N H Anderson; B J Rowlands; A Barbul
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

Review 10.  Oxygen-derived species: their relation to human disease and environmental stress.

Authors:  B Halliwell; C E Cross
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

View more
  5 in total

Review 1.  15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications.

Authors:  Tetsuo Arakawa; Kazuhide Higuchi; Yasuhiro Fujiwara; Toshio Watanabe; Kazunari Tominaga; Eiji Sasaki; Nobuhide Oshitani; Toshikazu Yoshikawa; Andrzej S Tarnawski
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

2.  S100A8 and S100A9 inhibit neutrophil oxidative metabolism in-vitro: involvement of adenosine metabolites.

Authors:  Herve Y Sroussi; Yu Lu; Qin L Zhang; Dana Villines; Phillip T Marucha
Journal:  Free Radic Res       Date:  2010-04

3.  Rebamipide enema therapy for left-sided ischemic colitis patients accompanied by ulcers: open label study.

Authors:  Satohiro Matsumoto; Kenichiro Tsuji; Satoshi Shirahama
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

4.  Rebamipide Suppresses Monosodium Urate Crystal-Induced Interleukin-1β Production Through Regulation of Oxidative Stress and Caspase-1 in THP-1 Cells.

Authors:  Seong-Kyu Kim; Jung-Yoon Choe; Ki-Yeun Park
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

5.  Differential effects of Bifidobacterium pseudolongum strain Patronus and metronidazole in the rat gut.

Authors:  Nadia Vasquez; Antonia Suau; Fabien Magne; Philippe Pochart; Marie-Agnès Pélissier
Journal:  Appl Environ Microbiol       Date:  2008-11-21       Impact factor: 4.792

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.